InVivo Therapeutics Holdings Corp. Announces Pricing of Public Offering of Common Stock and Warrants

InVivo Therapeutics Holdings Corp.
Posted on: 06 May 14
More InVivo Therapeutics Holdings Corp. press releases
InVivo Therapeutics Holdings Corp. (NVIV) a biomaterials company with innovative technologies for drug delivery with a focus on treatment of spinal cord injuries today announced the pricing of an underwritten public offering of 12175000 shares of common stock and warrants to purchase up to an aggregate of 6087500 shares of common stock at an offering price of $1.15 per share of common stock and $0.00001 per warrant. The warrants have a per share exercise price of $1.4375 125% of the public offering price of the common stock are exercisable immediately and expire five years from the date of issuance. In addition InVivo has granted the underwriters a 45-day option to purchase up to 1862250 additional shares of common stock and/or additional warrants to purchase up to 913250 additional shares of common stock to cover overallotments if any. The offering is expected to close on or about May 9 2014 subject to customary closing conditions.

The gross proceeds of the offering are expected to be approximately $14.0 million before deducting underwriting discounts and commissions and other estimated offering expenses excluding the exercise of any warrants. InVivo anticipates using the net proceeds from this offering for general corporate purposes including for research development and pre-clinical studies for its product candidates completion of its scaffold pilot clinical study and working capital.

Aegis Capital Corp. is the sole book-running manager for the offering.

This offering is being made pursuant to an effective shelf registration statement that the Company previously filed with the Securities and Exchange Commission (SEC) and was declared effective on January 19 2012. A preliminary prospectus supplement and accompanying prospectus relating to the offering were filed with the SEC and a final prospectus supplement and accompanying base prospectus will be available on the SEC's website www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to this offering when available may be obtained from Aegis Capital Corp. Prospectus Department 810 Seventh Avenue 18th Floor New York NY 10019 telephone: 212-813-1010 or email: [email protected]

This press release does not constitute an offer to sell or a solicitation of an offer to buy these securities nor shall there be any sale of these securities in any state or other jurisdiction in which such offer solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About InVivo Therapeutics Holdings Corp.

InVivo Therapeutics Holdings Corp. is a pioneering biomaterials company with unique technologies for drug delivery with a focus on treatment of spinal cord injuries. The Company was founded in 2005 with proprietary technology co-invented by Robert Langer ScD. Professor at Massachusetts Institute of Technology and Joseph P. Vacanti M.D. who is affiliated with Massachusetts General Hospital. In 2011 the Company earned the David S. Apple Award from The American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. The publicly traded company is headquartered in Cambridge MA. For more details visit www.invivotherapeutics.com.

Forward-Looking Statements

Statements made in this press release that do not describe historical facts or which apply prospectively are "forward-looking statements" within the meaning of the federal securities laws. These statements can be identified by words such as "believe" "anticipate" "intend" "estimate" "will" "may" "should" "expect" and similar expressions and relate to future events or the Company's future operating or financial performance and include statements regarding InVivo's offering of securities and intended use of the proceeds from the offering. Any forward-looking statements contained herein are based on current expectation and are subject to a number of risks and uncertainties. Given these uncertainties investors should not place undue reliance on these forward-looking statements. Factors that could cause actual results to differ materially from current expectations include whether InVivo will be able to complete the offering of common stock market conditions and the Company's ability to fulfill required closing conditions. Additional risk factors are included in InVivo's prospectus supplement related to this offering InVivo's Annual Report on Form 10-K for the year ended December 31 2013 as amended and other filings InVivo makes with the SEC including quarterly reports on Form 10-Q and current reports on Form 8-K. InVivo does not undertake to update these forward-looking statements.

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.